Assessment of the efficacy and safety of Etodolac in combined treatment of patients with knee osteoarthrosis
The article presents results of a study of the efficacy and safety of Etodolac versus Diclofenac Sodium in combined treatment of knee osteoarthrosis in patients of older age groups. Comparing values of the McGill Pain Questionnaire, the authors revealed reliable changes in rank and pain indices after 7 and 14 days of treatment in the group of patients, who took Etodolac. A reliable decrease of indices of the 4-component Visual Analogue Scale (VAS-1, VIS-2 on the 7th day of treatment, VAS-1-4 on the 14th day) was found out versus the patients, who took Diclofenac (a decrease of VAS-1 on the 14th day). The main group revealed a reliable decrease in the WOMAC-1,2 scale values versus the comparison group. Both groups demonstrated a reliable decrease in Lequesne’s algofunctional index scores and improved life quality values by the EroQol-5 questionnaire. During the period of observation, no undesirable phenomena or side effects caused by use of Etodolac were registered. Thus, the results of the authors’ own researches proved that use of Etodolac for treating knee osteoarthrosis was reasonable and had certain advantages, particularly in people of older age groups.
Full Text:PDF (Українська)
Kosarev V. V. Nonsteroidal anti-inflammatory drugs: evaluation of the efficacy and safety [Electronic resource] / V. V. Kosarev, S. A. Babanov // Consilium medicum. Neurology. — 2011. — № 2. — Access mode: http://con-med.ru/magazines/neurology/2934/2932/.
Povoroznyuk V. V. Musculoskeletal system diseases in people of all ages (selected works, overviews, articles). Three-volume / V. V. Povoroznyuk. — К., 2009. — 520 р.
Nonsteroidal anti-inflammatory drugs (methodology guidance) / L. S. Stratchounski, S. N. Kozlov, V. G. Kukes, V. Petrov. — Smolensk: Smolensk State Medical Academy, 2008. — 54 р.
Pharmacotherapy of the rheumatic diseases. Perspectives of application of Cox-2 Inhibitors in the treatment of osteoarthrosis [Electronic resource] / E. S. Tsvetkov, E. Yu. Panasiuc, N. G. Ionichenok, O. V. Rubtsov // Consilium medicum. — 2004. — № 2. — Access mode: http://www.consilium-medicum.com/medicum/article/12605.
Bacon P. A. Etodolac: efficacy in osteoarthritis and effects on chondrocyte function / P. A. Bacon // Rheumatol Int. — 1990. — Vol. 10. — Р. 3–7.
Bjarnason I. Gastrointestinal safety of NSAIDs and over-the-counter analgesics / I. Bjarnason // Int. J. Clin. Pract. — 2013. — Vol. 1 (178). — P. 37–42.
Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial / R. S. Bresalier, R. S. Sandler, H. Quan et al. // N. Engl. J. Med. — 2005. — Vol. 352 (11). — Р. 1092–1102.
Castellsague J. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project) / J. Castellsague, N. Riera-Guardia, B. Calingaert // Drug Saf. — 2012. — Vol. 35(12). — P. 1127–1146.
Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation / Y. F. Chen, P. Jobanputra, P. Barton et al. // Health Technol. Assess. — 2008. — Vol. 12 (11). — Р. 1–278.
EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT) / K. M. Jordan, N. K. Arden, M. Doherty et al. // Ann Rheum Dis. — 2003. — Vol. 62 (12). — P. 1145–1155.
Pelletier J. P. The pathophysiology of osteoarthritis and the implication of the use of hyaluronan and hylan as therapeutic agents in viscosupplementation / J. P. Pelletier , J. J. Martel-Pelletier // Rheumatol. Suppl. — 1993. — Vol. 39. — Р. 19–24.
The Risk of Acute Myocardial Infarction With Etodolac is Not Increased Compared to Naproxen: A Historical Cohort Analysis of a Generic COX-2 Selective Inhibitor / J. J. Warner, R. A. Weideman, K. C. Kelly et al. // J. Cardiovasc. Pharmacol. Ther. — 2008. — Vol. 13 (4). — Р. 252–260.
- There are currently no refbacks.
Copyright (c) 2014 Vladyslav Povorozniuk, Tatyana Orlik, Svetoslava Krochak, Tatyana Parakhina
This work is licensed under a Creative Commons Attribution 4.0 International License.